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Multiple Sclerosis (MS). The primary purpose of this study was
to examine the relationship between patients’ compliance to MS
specialty medications and the total health care (pharmacy and
medical) costs. METHODS: The study was conducted using a
retrospective study design utilizing all MS-related pharmacy and
medical claims maintained by a large PBM. Patients who were
diagnosed with MS and who have had at least one prescription
for specialty medications between July-December 2005 were
identiﬁed and selected for the analysis. Patient’s compliance to
specialty medications was assessed in terms of MPR. Patients
were categorized into three different groups as—compliant
(MPR > 0.8), partially compliant (MPR 0.5–0.8), and non-
compliant (MPR < 0.5). All drug costs; all medical non drug
costs as well as total health care costs were computed and
compared across the three groups using independent t-tests.
RESULTS: A total of 104 patients met the inclusion criteria and
were included for the analysis. Compliant group patients had
signiﬁcantly high all drugs cost and signiﬁcantly lower medical
non-drug cost as compared to the non-compliant and partially
compliant groups. The total health care costs were found to be
comparable and non-signiﬁcant among the three groups. CON-
CLUSION: Patients who were compliant to their specialty medi-
cations reported higher pharmacy cost and lower medical cost,
thereby implying that there exists an inverse relationship
between compliance and medical costs.
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OBJECTIVE: To evaluate pain, physical functioning, and
health-related quality of life (HRQoL) in patients after total
knee replacement (TKR) and to identify factors affecting these
outcomes. METHODS: This was a two-year non-randomized
prospective observational cohort study in knee osteoarthritis
(OA) patients undergone who as TKR. Patients were interviewed
one week before, six months after, and two years after surgery
using a standardized questionnaire including the SF-36, the
Oxford Knee Score (OKS), and the Knee Society Clinical Rating
Scale. Repeated measures ANOVA was performed to determine
which measurements signiﬁcantly changed over time. Univariate
and multiple linear regression analyses were used to identify
factors signiﬁcantly inﬂuencing the post-surgery outcomes.
RESULTS: A total of 298 (at baseline), 176 (at 6-months), and
111 (at 2-years) eligible patients were included in the data analy-
ses. The SF-36 physical functioning and role-physical scores, the
OKS, and the Knee Society Clinical Rating Scale scores were
signiﬁcantly improved after the surgery. Being younger, of
Chinese ethnicity and having a shorter duration of OA were
associated with greater improvement in post-surgery outcomes.
CONCLUSION: Physical functioning signiﬁcantly improved
after TKR, while other health domains remained stable after the
surgery. In order to obtain optimal beneﬁts from TKR, it is
important to increase public awareness and knowledge on OA in
Asian ethnic groups.
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OBJECTIVE: To assess quality of life (QoL) of outpatients with
rheumatoid arthritis (RA) in a real-life setting in Germany.
METHODS: This is a retrospective study analyzing records of
patients suffering from RA who were treated within an ambula-
tory rheumatology specialty. We assessed demographic data,
information on medication and additional therapies. QoL was
assessed using the Short Form-36 (SF-36). We performed a base-
line analysis (t0) followed by an analysis after 3, 6, 12, 18, and
24 months (t3–t24). RESULTS: A total of 636 patients were
included in the baseline analysis: 20.3% (n = 129) were male,
mean age was 55 years and average disease duration was 5.2
years. 83.3% (n = 530) patients were diagnosed with RA at the
ﬁrst visit (t0), in 16.7% (n = 106) of the cases, the RA was
diagnosed subsequently. Longitudinal data were available for
431 patients. On all SF-36 dimensions RA patients scored sig-
niﬁcantly lower than the general population matched for gender
and age (p = 0.05): A sub-group analysis revealed the following
signiﬁcant differences: in bodily pain insurees of the statutory
health insurance scored signiﬁcantly worse than enrollees of
private health insurance plans (p < 0.01). No signiﬁcant differ-
ences were observed between female and male RA patients at
baseline. QoL was higher at each assessment compared to base-
line for all dimensions but Role Emotional and General Health.
The longitudinal analysis showed QoL improved in all but one
dimension (Role Emotional) over the observation period of 24
months. This analysis is based on the last observation carried
forward method. CONCLUSION: RA patients have a signiﬁcant
reduction of QoL compared to the general population. Results
indicate that specialist treatment may help to improve QoL.
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OBJECTIVE: Patients with rheumatoid arthritis (RA) perceive
sleep quality as an important component of their quality of life.
Sleep is multi-dimensional and the objective is to investigate what
aspects of sleep improve when patients are treated with abata-
cept. METHODS: We used data from two randomized, double-
blind clinical trials of abatacept in patients with active RA in this
study: AIM and ATTAIN, in methotrexate and anti-TNF failures
respectively. Sleep quality was assessed using the validated
Medical Outcomes Study sleep questionnaire (MOS-sleep). The
treatment groups were compared on the seven derived MOS-
sleep scales: awakened short of breath or with headache, snoring,
sleep adequacy, sleep disturbance, somnolence, and sleep prob-
lems Index I and II. In addition, sleep duration (in hours) and
optimal sleep (yes vs no) based on the MOS-sleep module were
compared. Items are scored 0–100 with higher scores indicating
more of the attribute under consideration. Since all the attributes
for the scale scores are negative, a smaller number is better except
for sleep adequacy which is a positive attribute. Optimal sleep is
a binary variable with one indicating optimal sleep, so a higher
proportion on this variable is better. RESULTS: There was no
pertinent difference at baseline in the various items on the MOS
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sleep questionnaire or on the derived MOS sleep scales. Signiﬁ-
cant improvement in the abatacept group compared to control
on sleep adequacy, sleep disturbance, somnolence and both sleep
problem indices I and II were found. For both studies,
sleep quantity was not signiﬁcantly difference between treatment
groups, but optimal sleep signiﬁcantly improved in the abatacept
vs control group: ATTAIN (18% vs -12%, p < 0.0001) and AIM
(16% vs 5%, p = 0.0214). CONCLUSION: Treatment with
abatacept improves several different aspects of sleep in RA
patients. In particular, sleep disturbance and sleep problems
given by index II are reduced, and optimal sleep is improved.
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OBJECTIVE: To examine the validity, reliability, and sensitivity
to change of a simple measure of activity participation for rheu-
matoid arthritis (RA) clinical trials. Joint damage from RA sig-
niﬁcantly limit patients’ participation of daily work and
non-work activities, however, few instruments were available to
measure treatment effect on this aspect. METHODS: We mea-
sured activity participation in two randomized clinical trials of
abatacept in active RA patients. Activity participation was
assessed by two items: 1) the number of days in the past month
a patient was unable to perform usual activities (paid or unpaid
work, or any other daily activities), and 2) how often a patient
was able to perform activities completely (scored 1–6, ranging
from none to all of the time). For construct validity, corre-
lations between the two activity items with clinical response
and patient-reported outcomes were examined. Intraclass corre-
lation coefﬁcient (ICC) was used to assess test-retest reliability,
and standardized effect sizes (SES) were calculated to evaluate
sensitivity to change. RESULTS: In both studies at baseline,
patients were limited for 15 days per month in usual activities
and the score on activity completion was 3.7. After treatment,
patients with EULAR clinical responses of good, moderate,
none, gained back 11, 9, and 4 days of activity respectively, and
patients who achieved minimal disease activity state gained
12 days vs. those who did not (7 days). Similar pattern was
observed for the activity completion score. Moderate to strong
correlations (0.5–0.6) between the two activity items with
physical function, patient global, pain, and fatigue were found.
The ICC for reliability was 0.6, and the SES was 0.5, indicating
good response to change. CONCLUSION: The simple activity
participation measure reﬂects true changes in patient clinical
status and quality of life. It is valid, reliable, and sensitive to
change, which suggests it is a suitable outcomes measure for
clinical trials.
PMS38
ESTIMATINGWORK PRODUCTIVITY: EFFECTS OFTRAMADOL
EXTENDED-RELEASETREATMENT
Benson C1, Chang H2, Lerner D2, Rogers W2, Mody S1, Schein JR1
1Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA,
2Tufts-New England Medical Center, Boston, MA, USA
OBJECTIVE: To estimate work productivity for patients treated
with tramadol extended–release (ER) or placebo. METHODS:
Intent-to-treat patients (18–65 years old) with chronic osteoar-
thritis pain from a 12-week, randomized, double-blind, placebo-
controlled, ﬁxed-dose study and treated with tramadol ER
(100–400 mg) or placebo were compared. Work productivity
was not assessed within the study, it was estimated using an
imputation methodology. This imputation method cross-walks
other health measures into Work Limitations Questionnaire
(WLQ) scores. The WLQ is a validated questionnaire assessing
health-related decrements in job performance and work produc-
tivity (“presenteeism”). According to this method, mean change
in the Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis total index scores were multiplied by the regres-
sion coefﬁcients established for the WLQ and WOMAC. Produc-
tivity gains were translated to annual US dollars inﬂated to 2007.
RESULTS: Baseline characteristics of tramadol ER and placebo
groups were comparable. After 12 weeks of treatment, the tra-
madol ER treated patients signiﬁcantly improved than placebo
(WOMAC score of 23 vs. 16 points, p = 0.002). This 23 points
improvement in WOMAC when imputed to WLQ translated
into improvement of WLQ time management (8.15%), physical
demands (11.78%), mental-interpersonal (5.99%), overall
output demands (6.95%) and improvement in work productivity
(1.96%). The improvement observed in the tramadol ER patients
when aggregated to annual dollars per employee in 2007 ranged
from [$1201–$7218], was numerically higher than placebo
treated patients [$882–$5098]. Sensitivity analyses using other
health-measures resulted in similar ﬁndings. CONCLUSION:
Treatment with tramadol ER resulted in signiﬁcant improvement
in pain and physical function, when imputed to WLQ corre-
sponded to productivity improvement.
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OBJECTIVE: To estimate loss of employable life-years over time
in patients with rheumatoid arthritis (RA). METHODS: We used
a Markov model to estimate employable life-years using data
from ASPIRE, a randomized clinical trial comparing the efﬁcacy
and safety of inﬂiximab + methotrexate (MTX) (IFX group)
and placebo + MTX (MTX group) among early RA patients.
Employability state was deﬁned as ‘unemployable’ if patients
were unemployed and felt unable to work even if a job was
available or ‘employable’ if patients were employed or felt well
enough to work if a job were available. The one-year transition
probability of employability was estimated using a logistic
regression model, and loss of employable life-years was estimated
using a two-state Markov model. RESULTS: For a patient at age
45 years, 31.4 % of female and 29.7% of male were unemploy-
able using the regression model. For patients starting at age 45
and employable, the probability of remaining employable after
one-year of treatment was 0.928 in males and 0.905 in females in
the IFX group, and 0.899 in males and 0.867 in females in the
MTX groups, respectively. For patients unemployable, the prob-
ability to be employable after one-year treatment was 0.481 in
males and 0.405 in females in the IFX groups, and 0.390 in males
and 0.319 in females in the MTX groups, respectively. In the
Markov model, after 10 years at age 55, 18.5% of females and
14.1% of males in the IFX groups, and 30.7% of females and
24.2% of males in the MTX groups will be unemployable. On
average, 0.99 employable life-years will be saved per patient over
10 years in IFX-treated patients compared to MTX-treated
patients. CONCLUSION: This analysis presents a new method
to estimate employable life-years using a Markov model, and
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